Foundayo (orforglipron): the 2026 GLP-1 guide

Overview

Orforglipron — sold under the brand name Foundayo — became the first non-peptide oral GLP-1 receptor agonist approved by the U.S. FDA on April 1, 2026¹. Unlike Rybelsus (semaglutide oral), Foundayo’s small-molecule design lets patients take it any time of day, with or without food or water.

Clinical Efficacy

In the pivotal ATTAIN-1 trial (n=adults with obesity, no T2D), Foundayo produced an average 12.4% body weight loss over 72 weeks at the highest dose (efficacy estimand)². In ATTAIN-2 (T2D + obesity), the 36 mg dose produced 10.5% weight loss versus 2.2% on placebo³.

For type-2 diabetes (a separate indication track), ACHIEVE-1 showed A1c reductions of 1.2%, 1.5%, and 1.5% at the 3 / 12 / 36 mg doses respectively, with 7.9% weight loss at 36 mg over 40 weeks.

Dosing & Titration

The FDA-approved Foundayo Prescribing Information specifies six tablet strengths and a strict 30-day-minimum escalation schedule⁴:

• 0.8 mg — starting dose (titration only)
• 2.5 mg — after at least 30 days at 0.8 mg
• 5.5 mg — after at least 30 days at 2.5 mg (first maintenance therapeutic dose)
• 9 mg — therapeutic
• 14.5 mg — therapeutic
• 17.2 mg — maximum approved dose

Patients escalate based on tolerability and treatment response, with at least 30 days at each step. Most clinical-trial efficacy data reflect the 17.2 mg maintenance dose.

Side Effects

Boxed Warning — Risk of Thyroid C-Cell Tumors

Like all GLP-1 receptor agonists, Foundayo carries an FDA Boxed Warning for risk of thyroid C-cell tumors⁴. Foundayo is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The relevance of rodent C-cell tumor findings to humans is not established, but the contraindication is class-wide and absolute.

Common adverse reactions (pooled Trials 1 & 2, at the 17.2 mg maintenance dose)

Incidence is dose-dependent — rates at 5.5 mg and 9 mg are meaningfully lower than at 17.2 mg⁴. Most GI events occur during titration and improve with continued treatment.

Other warnings & precautions

The label also flags acute pancreatitis, severe GI reactions (~3% on Foundayo vs ~1% placebo), acute kidney injury (typically dehydration-driven from GI events), hypoglycemia when combined with insulin or sulfonylureas, hypersensitivity reactions, diabetic retinopathy progression in patients with diabetes, acute gallbladder disease, and pulmonary aspiration risk during anesthesia (Foundayo delays gastric emptying)⁴.

2026 Availability

Foundayo launched in the U.S. in April 2026 through LillyDirect and partner pharmacies. Cash self-pay starts at $149/month for the lowest dose; the commercial savings card brings eligible insured patients to as low as $25/month¹.

Beginning July 1, 2026, all Foundayo formulations are covered under the new Medicare GLP-1 Bridge program at a flat $50/month copay for eligible Part D beneficiaries (BMI ≥ 27 with qualifying comorbidity, or BMI ≥ 35 alone)⁵. The Bridge program runs through December 31, 2027.